CYTENA BPS and Leadgene Bio to Level Up Taiwan’s Protein Drugs Production

Biological drugs such as monoclonal antibodies originated from mammalian cells and the culture is transited into large-scale manufacturing afterward, hence the development and incubation of cell lines play key roles in the quality and quantity of protein drug production.

However, traditional cell line development (CLD) is often limited by the size of the static format due to the size of the well plate and the form of the incubation, limiting the number of cells, thus slowing down the progress of drug development.

In order to increase the output of Taiwan’s biomedicine, CYTENA BPS announced the partnership with LeadgeneBio, a biotechnology company dedicated to antibody drugs and diagnostic reagents development, to build a new manufacturing site to level up the production of Taiwan’s protein drugs.  

Yung-Chun Chuang, the CEO of LeadgeneBio stated, “Not only can the partnership with CYTENA BPS to deliver the automated cell line development platform help save time and money, but it also provides highly efficient and high throughput drug developing service for downstream pharmaceutical companies.”

Automated Cell Culture Accelerates Cell Growth

Traditional cell culture methods usually come with several downsides, such as limited oxygen transfer and unstable pH levels in the incubation environment, thus increasing variable factors in cell incubation. 

With CYTENA BPS’s strength in increasing the efficacy of early-stage cell line selection and its real-time, longitudinal monitoring systems, the S.NEST microbioreactors coming with the new site, can provide a better microscale environment, increasing the throughput and quality of cell incubation workflow, and improving the production of recombinant protein and antibody drugs.

Another feature highlight of S.NEST is that it provides the optimal environment for cell incubation with its integrated system. With the combination of its patented condenser, along with the built-in sensor monitoring dissolvable O2 level and pH level, S.NEST can overcome the evaporation concern that comes with mixing cultures. Overall, with the high quality of experiment background provided to the drug candidates’ development, S.NEST allows all pharmaceuticals to utilize biomedicine, protein drugs, and CDMO services.

Leveling Up Protein Drugs Selection Workflow and Throughput 

The automated workflow is the new trend for biologics production. Aside from the automated cell culture technology, CYTENA BPS is also developing more tools with high efficiency and automated cell culture workflows for biologics, drug screening, and functional genomics applications.

“By being connected with CYTENA BPS’s experience and profession, we are excited to build an automated cell line selection platform with Leadgene Bio. Together, we hope to accelerate the workflow and increase the throughput for the biology industry, ” said Charles Tsai, the CEO of CYTENA BPS.

Author

Aurora Mau